Pluri (NASDAQ:PLUR) Shares Set to Reverse Split on Monday, April 1st

Pluri Inc. (NASDAQ:PLUR)’s stock is scheduled to reverse split before the market opens on Monday, April 1st. The 1-8 reverse split was announced on Monday, April 1st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 1st.

Pluri Trading Down 13.7 %

Shares of NASDAQ:PLUR opened at $0.88 on Thursday. The stock has a 50 day moving average of $0.81 and a 200 day moving average of $0.65. The company has a market cap of $36.49 million, a PE ratio of -1.52 and a beta of 1.45. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 3.69. Pluri has a 12-month low of $0.43 and a 12-month high of $1.07.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Monday, February 12th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $0.11 million for the quarter. Pluri had a negative net margin of 6,708.40% and a negative return on equity of 177.94%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC grew its stake in shares of Pluri by 128.1% during the 4th quarter. Citadel Advisors LLC now owns 57,481 shares of the company’s stock valued at $33,000 after acquiring an additional 32,279 shares during the period. Jane Street Group LLC bought a new position in Pluri in the 3rd quarter worth approximately $28,000. Values First Advisors Inc. boosted its stake in Pluri by 168.4% in the 3rd quarter. Values First Advisors Inc. now owns 135,547 shares of the company’s stock worth $81,000 after purchasing an additional 85,037 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Pluri in the 3rd quarter worth approximately $81,000. 16.59% of the stock is currently owned by institutional investors.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.